(Q46851893)

English

A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats

scientific article published in November 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Joshua L Lachowicz

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

Gerald S Post

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

Edwin Brodsky

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

publication date

1 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

Journal of Veterinary Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

19

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

860-864

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1939-1676.2005.TB02778.X

21 January 2018

C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1939-1676.2005.TB02778.X

21 January 2018

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1939-1676.2005.TB02778.X

21 January 2018

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1939-1676.2005.TB02778.X

21 January 2018

Identifiers

10.1111/J.1939-1676.2005.TB02778.X

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16355681

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46851893&oldid=2134724086"